A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Afatinib (Primary) ; Monalizumab (Primary) ; Palbociclib (Primary) ; Bleomycin; Bleomycin; Bleomycin; Docetaxel; Fluorouracil; Gemcitabine; Methotrexate; Mitomycin; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms UPSTREAM
- 12 Nov 2018 According to Innate Pharma media release, data from thi study will be presented at SITC 2018 Annual Meeting .
- 16 Oct 2018 According to Innate Pharma media release, data from thi study will be presented at the ESMO 2018 Congress.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.